Annual Report 2022
Department of Cardiovascular Medicine
Kazuko Tajiri
Introduction
In the Department of Cardiology, cardiovascular management for cancer patients is conducted. This specifically includes the assessment of cardiovascular risks before surgery or cancer drug therapy, optimization of cardiovascular conditions, early detection and intervention of cardiovascular toxicity through monitoring during cancer drug therapy with cardiovascular toxicity, long-term monitoring after cancer drug therapy, and management of cancer treatment-related cardiovascular diseases.
The Team and What We Do
In 2022, there were 2,325 consultations for new patients and 281 follow-up patients, with a total of 2,606 patients. In cases requiring emergency interventions such as catheter treatment or advanced intensive care, patients are promptly transferred to nearby specialized cardiovascular hospitals, ensuring close collaboration for treatment.
Research Activities
Some clinical studies and translational research are conducted on various cardiovascular issues faced by patients with cancer, including immune checkpoint inhibitor-related myocarditis, cancer therapy-related cardiac dysfunction, and venous thrombosis, with a focus on elucidating the pathophysiology, conducting real-world investigations, and exploring early detection and treatment. In 2022, Nine English-language papers, 8 Japanese-language papers, and 1 authored book were published.
Education
Education related to cardio-oncology was conducted through regular meetings with oncologists, physiological testing technicians, nurses, and pharmacists.
Future Prospects
Pre-treatment evaluation of the cardiovascular system, monitoring after treatment initiation, and appropriate treatment when cardiovascular toxicity occurs are essential to achieve the maximum effectiveness of cancer treatment. This necessitates a thorough understanding of cancer treatments as well as the improvement of cardiovascular management tailored to them. Furthermore, it is important not only to train experts in cardiovascular oncology, but also to provide general cardiologists with the necessary cardiovascular oncology practice skills.
List of papers published in 2022
Journal
1. Inoue K, Tajiri K, Xu D, Murakoshi N, Ieda M. Risk Factors and In-Hospital Outcomes of Perioperative Atrial Fibrillation for Patients with Cancer: A Meta-Analysis. Annals of surgical oncology, 30:711-721, 2023
2. Tajiri K, Inoue K. ASO Author Reflections: Perioperative Atrial Fibrillation in Patients Undergoing Cancer Surgery. Annals of surgical oncology, 30:722, 2023
3. Inoue K, Tajiri K, Xu D, Murakoshi N, Ieda M. ASO Visual Abstract: Risk Factors and In-Hospital Outcomes of Perioperative Atrial Fibrillation in Patients with Cancer: A Meta-analysis. Annals of surgical oncology, 30:723-724, 2023
4. Negishi T, Thavendiranathan P, Penicka M, Lemieux J, Murbraech K, Miyazaki S, Shirazi M, Santoro C, Cho GY, Popescu BA, Kosmala W, Costello B, la Gerche A, Mottram P, Thomas L, Seldrum S, Hristova K, Bansal M, Kurosawa K, Fukuda N, Yamada H, Izumo M, Tajiri K, Sinski M, Vinereanu D, Shkolnik E, Banchs J, Kutty S, Negishi K, Marwick TH. Cardioprotection Using Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy: 3-Year Results of the SUCCOUR Trial. JACC. Cardiovascular imaging, 16:269-278, 2023
5. Tajiri K, Suehara Y, Suzuki T, Sekine I. Clonal heamatopoiesis and associated cardiovascular diseases. Japanese journal of clinical oncology, 53:187-194, 2023
6. Osawa T, Tajiri K. Neoplastic Cardiac Tamponade. Internal medicine (Tokyo, Japan), 2023
7. Nagai T, Inomata T, Kohno T, Sato T, Tada A, Kubo T, Nakamura K, Oyama-Manabe N, Ikeda Y, Fujino T, Asaumi Y, Okumura T, Yano T, Tajiri K, Matsuura H, Baba Y, Sunami H, Tsujinaga S, Ota Y, Ohta-Ogo K, Ishikawa Y, Matama H, Nagano N, Sato K, Yasuda K, Sakata Y, Kuwahara K, Minamino T, Ono M, Anzai T. JCS 2023 Guideline on the Diagnosis and Treatment of Myocarditis. Circulation journal, 87:674-754, 2023
8. Kosuge H, Nakamura M, Oyane A, Tajiri K, Murakoshi N, Sakai S, Sato A, Taninaka A, Chikamori T, Shigekawa H, Aonuma K. Potential of Gold Nanoparticles for Noninvasive Imaging and Therapy for Vascular Inflammation. Molecular imaging and biology, 24:692-699, 2022
9. Iida N, Tajiri K, Ishizu T, Sasamura-Koshizuka R, Nakajima H, Kawamatsu N, Sato K, Yamamoto M, Machino-Ohtsuka T, Bando H, Sekine I, Kawakami Y, Ieda M. Echocardiography image quality of global longitudinal strain in cardio-oncology: a prospective real-world investigation. Journal of echocardiography, 20:159-165, 2022
10. Murakata Y, Tajiri K. A Diverse Range of Cardiac Adverse Events Associated with Immune Checkpoint Inhibitor Therapy. Internal medicine (Tokyo, Japan), 61:2099-2100, 2022
11. Tajiri K, Sekine I. Atherosclerotic cardiovascular events associated with immune checkpoint inhibitors in cancer patients. Japanese journal of clinical oncology, 52:659-664, 2022
12. Inoue K, Tajiri K. Galectin-3 as an Arrhythmogenic Predictive Marker for Heart Failure. Internal medicine (Tokyo, Japan), 61:933-934, 2022
13. Yamamoto M, Tajiri K, Ayuzawa S, Ieda M. Pathological findings of clinically suspected myocarditis temporally associated with COVID-19 vaccination. European journal of heart failure, 24:1132-1138, 2022
14. Shimoda Y, Murakoshi N, Mori H, Xu D, Tajiri K, Hemmi Y, Sato I, Noguchi M, Nakamura Y, Hayashi Y, Ieda M. Generation of a human induced pluripotent stem cell line derived from a patient with dilated cardiomyopathy carrying LMNA nonsense mutation. Stem cell research, 62:102793, 2022
15. Nakagomi Y, Tajiri K, Shimada S, Li S, Inoue K, Murakata Y, Murata M, Sakai S, Sato K, Ieda M. Immune Checkpoint Inhibitor-Related Myositis Overlapping With Myocarditis: An Institutional Case Series and a Systematic Review of Literature. Frontiers in pharmacology, 13:884776, 2022
16. Yuan Z, Murakoshi N, Xu D, Tajiri K, Okabe Y, Aonuma K, Murakata Y, Li S, Song Z, Shimoda Y, Mori H, Aonuma K, Ieda M. Identification of potential dilated cardiomyopathy-related targets by meta-analysis and co-expression analysis of human RNA-sequencing datasets. Life sciences, 306:120807, 2022
17. Nowatzke J, Guedeney P, Palaskas N, Lehmann L, Ederhy S, Zhu H, Cautela J, Francis S, Courand PY, Deswal A, Ewer SM, Aras M, Arangalage D, Ghafourian K, Fenioux C, Finke D, Peretto G, Zaha V, Itzhaki Ben Zadok O, Tajiri K, Akhter N, Levenson J, Baldassarre L, Power J, Huang S, Collet JP, Moslehi J, Salem JE. Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: Report from an international registry. European journal of cancer (Oxford, England : 1990), 177:197-205, 2022
18. Aonuma K, Xu D, Murakoshi N, Tajiri K, Okabe Y, Yuan Z, Li S, Murakata Y, Tominaga K, Nogami A, Aonuma K, Ieda M, Isoda H. Novel preventive effect of isorhamnetin on electrical and structural remodeling in atrial fibrillation. Clinical science (London, England : 1979), 136:1831-1849, 2022
19. Murakata Y, Yamagami F, Murakoshi N, Xu D, Song Z, Li S, Okabe Y, Aonuma K, Yuan Z, Mori H, Aonuma K, Tajiri K, Ieda M. Electrical, structural, and autonomic atrial remodeling underlies atrial fibrillation in inflammatory atrial cardiomyopathy. Frontiers in cardiovascular medicine, 9:1075358, 2022